Biotechnology
Eligo Publishes in Nature a Landmark Study That Unlocks Genome Editing of Bacteria in the Gut
PARIS, July 10, 2024 /PRNewswire/ -- For the first time, a team of scientists at Eligo has demonstrated it was possible to genetically modify bacteria with nearly 100% efficiency directly in the gut of animals. This work provides scientists with a novel strategy to better understand how genes fro...
2024-07-10 23:00
2180
3D Artificial Cornea from Stem Cells: Chula Researchers Advance Canine Corneal Wound Treatment
BANGKOK, July 10, 2024 /PRNewswire/ -- Chulalongkorn University's Faculty of Veterinary Science and the Faculty of Engineering have worked together to research and develop a three-dimensional artificial cornea from stem cells that offers a way to treat deep corneal wounds in dogs. The innovation ...
2024-07-10 09:00
3032
MGI Tech Partners with Australian Research Council Training Centre CEAStAR to Lead Innovation in Antimicrobial Resistance Solutions
BRISBANE, Australia, July 8, 2024 /PRNewswire/ -- MGI Australia Pty Ltd, subsidiary of MGI Tech Co., Ltd., a company committed to building core tools and technologies that drive innovation in life science, proudly announces its strategic partnership with TheUniversity of Queensland(UQ) led Centre...
2024-07-08 17:14
3000
Sirnaomics Announces Interim Results for Successful Completion of the Second Cohort of Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Therapeutics
HONG KONG and GERMANTOWN, Md. and SUZHOU, China, July 8, 2024 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", together with its subsidiaries, the "Group" or " Sirnaomics"; stock code: 2257), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, to...
2024-07-08 14:30
3217
Olverembatinib Approved for Commercialization in Macau China
ROCKVILLE, Md. and SUZHOU, China, July 8, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first- and best-in-class therapies for hematological malignancies, announced today that its novel BCR-ABL1 tyro...
2024-07-08 08:55
3317
XPOVIO® (selinexor) Approved for New Indication in DLBCL in China, Bringing a New Treatment Option to Patients in the Country
- Following its initial approval for the treatment of relapsed/refractory multiple myeloma (R/R MM), XPOVIO® has now received approval as a monotherapy for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) marking the second approved indication of ...
2024-07-05 21:18
7565
LakeShore Biopharma to Hold an Extraordinary General Meeting on July 25, 2024, Pursuant to Shareholders' Requisition
GAITHERSBURG, Md., July 5, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for in...
2024-07-05 19:00
5696
Innovent and IASO Bio Enhance Strategic Collaboration in Cell Therapy
SAN FRANCISCO and SUZHOU, China, July 5, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic,...
2024-07-05 16:30
5952
Ascentage Pharma Received US$100 Million Option Payment from Takeda
ROCKVILLE, Md. and SUZHOU, China, July 4, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first-in-class and best-in-class therapies for hematological malignancies, announced today that onJuly 2, 2024,...
2024-07-04 08:28
5331
/C O R R E C T I O N -- Menarini Silicon Biosystems/
In the news release, Menarini's cell based non-invasive prenatal technology demonstrates high resolution detection of fetal genomic abnormalities from a simple maternal blood draw, issued02-Jul-2024 by Menarini Silicon Biosystems over PR Newswire, we are advised by the company that the subheadlin...
2024-07-03 03:24
3489
PolyU study reveals the mechanism of bio-inspired control of liquid flow, enlightening breakthroughs in fluid dynamics and nature-inspired materials technologies
HONG KONG, July 2, 2024 /PRNewswire/ -- The more we discover about the natural world, the more we find that nature is the greatest engineer. Past research believed that liquids can only be transported in fixed direction on species with specific liquid communication properties and cannot switch th...
2024-07-02 20:25
3044
Angel Yeast Partners with ffit8 to Launch Nougat Protein Bar and Protein Nougat Snack
SHANGHAI, July 2, 2024 /PRNewswire/ -- Angel Yeast
2024-07-02 20:00
13459
Pulnovo Medical Announces First Enrollment in Portugal for Global Clinical Study of PADN Technology in Treating Pulmonary Hypertension Associated with Left Heart Disease
SHANGHAI, July 2, 2024 /PRNewswire/ -- Pulnovo Medical Limited, a globally recognized device pioneer in the treatment of Pulmonary Hypertension (PH) and Heart Failure (HF), is pleased to announce the successful initiation and first two patients enrollment for its global multicenter clinical study...
2024-07-02 19:10
2949
HiRO acquires CRO DeltaMed Solutions, continues to expand cross-border operations in the US
WILMINGTON, Del., July 2, 2024 /PRNewswire/ -- Harvest Integrated Research Organization (HiRO), a full-service, boutique global CRO, is excited to announce its latest strategic move with the successful acquisition of DeltaMed Solutions, an emerging CRO with a robust foothold in the US. The acquis...
2024-07-02 10:00
4492
Innovent Announces Oral Presentation at the ESMO Gastrointestinal Cancers Congress 2024 on Latest Clinical Data of Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
SAN FRANCISCO and SUZHOU, China, July 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune,...
2024-07-02 08:00
4521
Bridgewest Perth Pharma gains strategic edge with noted Australian Executive John Van Der Wielen on Board
PERTH, Australia, July 2, 2024 /PRNewswire/ -- Bridgewest Perth Pharma, global pharmaceutical holding company withNovaCina CDMO division and LumaCina pharmaceutical supply division, announces the addition of renown Australian executiveJohn Van Der Wielen to Board of Directors. Van Der Wielen will...
2024-07-02 07:00
2685
HistoIndex Charts New Course in Liver Disease Innovation: Announces Pivotal Changes to Scientific Advisory Board
* Company to appoint Prof. Arun J. Sanyal as the new Chairman of HistoIndex's Scientific Advisory Board, bringing unparalleled expertise to guide future innovations. * Prof. Vlad Ratziu joins the Scientific Advisory Board to strengthen the Company's global scientific leadership in liver disea...
2024-07-01 20:00
3236
SCG Cell Therapy Announces FDA IND Clearance of SCG142, a next-generation HPV-specific TCR T cell therapy for patients with HPV-associated solid tumors
SINGAPORE, July 1, 2024 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a biotechnology company developing novel immunotherapies for infectious diseases and their associated cancers, today announced that U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) appl...
2024-07-01 10:56
2675
Hasten Announces Acquisition of 14 Celltrion Legacy Products, Accelerating its Business Expansion in the Pan-Asia Area
SHANGHAI, June 28, 2024 /PRNewswire/ -- Hasten Biopharmaceutical Co., Ltd. (referred to as "Hasten") announced today that it has successfully acquired the asset rights of 14 branded products across Pan-Asia countries and regions from Celltrion, a Korean biopharmaceutical company. According to the...
2024-06-28 16:26
7858
Sirnaomics Announces Completion of STP707 Phase I Clinical Study with Strong Safety Profile and Disease Activity for the Treatment of Pancreatic Cancer Patients
HONG KONG, GERMANTOWN, Md. and SUZHOU, China, June 28, 2024 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", together with its subsidiaries, the "Group" or " Sirnaomics"; stock code: 2257), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, toda...
2024-06-28 13:44
3363
Week's Top Stories
Most Reposted
Amorepacific Showcases Innovative Technologies at CES 2026
[Picked up by 291 media titles]
2026-01-05 12:14
Radisson Hotel Group Revives Bangkok Icon with Opening of Radisson Hotel Chateau de Bangkok
[Picked up by 283 media titles]
2026-01-06 10:45
Panduit Announces Key Executive Appointments to Support Strategic Growth and Innovation
[Picked up by 282 media titles]
2026-01-07 10:00
iQIYI LAND Yangzhou to Open on February 8, Marking New Chapter in China's Immersive Entertainment Scene
[Picked up by 280 media titles]
2026-01-01 10:00
Space Summit 2026 to Convene Global Leaders in Singapore to Address the Growing Space Economy
[Picked up by 272 media titles]
2026-01-07 15:27Most Read
China Daily Launches "China Bound" -- An English-Language Smart-Tourism Service Platform for International Travelers
2026-01-01 17:04
9027
iQIYI LAND Yangzhou to Open on February 8, Marking New Chapter in China's Immersive Entertainment Scene
2026-01-01 10:00
8274
Domestic GPU Leader Biren Technology Listed on Hong Kong Stock Exchange
2026-01-02 17:41
7661
